Your search for "Eyes" found 11 matches:
University of Colorado Age-Related Macular Degeneration Registry

Do you have dry Age-Related Macular Degeneration (AMD)? If yes, you may be eligible to participate in our research study....

Protocol #: 14-0740

Tivanisiran for Dry Eye in Subjects with Sjogren's Syndrome

The purpose of this study is to compare the safety and effectiveness of tivanisiran sodium ophthalmic solution (eye drops) to placebo for treating signs and symptoms of DED in participants with a documented diagnosis of dry eye associated with Sjögren’s Syndrome. ...

Protocol #: 21-2624

Zoster Eye Disease Study (ZEDS): A multi-center, randomized, double-masked, placebo-controlled clinical trial of suppressive valacyclovir for one year in immunocompetent study participants with an episode of dendriform epithelial keratitis, stromal keratitis, endothelial keratitis, and/or iritis due to Herpes Zoster Ophthalmicus (HZO) in the year prior to enrollment *NOTE: THIS STUDY IS NO LONGER ENROLLING NEW SUBJECTS*

This study is looking to see if treatment with 12 months of daily valacyclovir medication reduces the development of certain types of new or worsening eye disease; specifically, infection on the surface of the front of the eye (cornea), inflammation of the cornea, or inflammation inside th...

Protocol #: 17-0585

An Open-label, Phase 1/2 Trial of Gene Therapy 4D-125 in Males with X-linked Retinitis Pigmentosa (XLRP) Caused by Mutations in the RPGR Gene

This is a multicenter study with two parallel parts: an observational Natural History Cohort and an open-label, prospective interventional trial in males with non-syndromic XLRP due to mutations in RPGR. The target population is restricted to avoid confounding atypical presentation in fema...

Protocol #: 20-0130

A Phase 2 trial of AU-011 via suprachoroidal administration with a dose escalation phase (open-label, ascending single and repeat dose) and a randomized, masked dose expansion phase designed to evaluate the safety and efficacy of AU-011 in subjects with primary indeterminate lesions and small choroidal melanoma

This study is being conducted on patients diagnosed with a type of eye cancer called choroidal melanoma or an indeterminate lesion (a growth in your eye that is suspected to be melanoma), also known as eye melanoma. People who have choroidal melanoma are usually treated with radiation ther...

Protocol #: 20-1186

A Multi-Center, Randomized, Double-Masked, Vehicle-Controlled, Parallel-Group, Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Stage 2 and 3 Neurotrophic Keratitis Subjects

Patients diagnosed with stage 2 (persistent epithelial defect) or stage 3 (corneal ulcer) Neurotrophic Keratitis (NK) will take part in this study. Neurotrophic Keratitis (also called neurotrophic keratopathy) is a rare disease of the cornea that occurs when the nerves to the cornea do not...

Protocol #: 21-3923

A Phase 3 Randomized, Active-Controlled, Double-Masked Study to Evaluate the Safety and Efficacy of TRS01 Eye Drops in the Treatment of Subjects with Active Non-infectious Anterior Uveitis including Subjects with Uveitic Glaucoma

The effects of TRS01 eye drops will be compared to an FDA approved corticosteroid eye drop. Doctors commonly use anti-inflammatory drugs called corticosteroids delivered as eye drops to reduce the inflammation and treat anterior non-infectious uveitis. However, continued use of corticoster...

Protocol #: 21-4454


Protocol #: 21-2605

Location: Childrens Hospital Colorado

NAVEG test administration for Cerebral Vision Impairment (CVI) in premature infants

Protocol #: 21-3043

Location: Childrens Hospital Colorado

A Randomized Trial of Low-Dose Bevacizumab versus Laser for Type 1 Retinopathy of Prematurity (ROP3)

Protocol #: 21-3951

Location: Childrens Hospital Colorado

A multiple ascending dose (MAD) safety, tolerability and efficacy study of VRDN-001, a humanized monoclonal antibody directed against the IGF-1 receptor, in normal healthy volunteers (NHVs) and subjects with thyroid eye disease (TED)

Protocol #: 21-4929

Location: Outpatient CTRC, University of Colorado Hospital